Randomized double-blind, placebo-controlled clinical trial of a selective 5-lipoxygenase inhibitor (AA-861) for the prevention of seasonal allergic rhinitis.
In a randomized, double-blind, parallel group trial conducted in eight European centres, the 5-lipoxygenase inhibitor AA-861 was administered orally, starting 2 weeks before the pollen season and continuing for 8 weeks; after the start of the season escape medication was permitted if necessary. Patients were enrolled who had a previous history of pollen allergy, confirmed by skin prick tests and/or relevant allergen-specific immunoglobulin E to pollen. Daily symptoms scores were recorded on diary cards and assessments were made by the investigator during the study period. Better global improvement ratings were achieved using AA-861, as assessed both by the investigators and the patients. The total nasal symptoms scores and activities of daily living were also improved compared to placebo. No significant adverse reactions were encountered.
Ancill
R J
RJ
Institute of Clinical Pharmacology, Regensdorf, Zurich, Switzerland.
Takahashi
Y
Y
Kibune
Y
Y
Campbell
R
R
Smith
J R
JR
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D016227:Benzoquinones; D001772:Blood Cell Count / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016859:Lipoxygenase Inhibitors; D008297:Male; D008875:Middle Aged; D011809:Quinones / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D006255:Rhinitis, Allergic, Seasonal / Q000517:prevention & control*
D016227:Benzoquinones; D016859:Lipoxygenase Inhibitors; D011809:Quinones; C036837:2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone